Two biotech firms raise $556 million in combined IPOs

Seaport Therapeutics and Hemab Therapeutics launched initial public offerings on Thursday, together bringing in $556.4 million to fund further development of their drug pipelines.

Hemab Therapeutics raised $301.5 million by selling nearly 17 million shares at $18 each. The company increased the size of its offering by 27% shortly before pricing, adding roughly $50 million to the proceeds.

Seaport Therapeutics collected $254.9 million, selling more than 14 million shares at $18 each, and became the first biotechnology company focused on neurological disorders to go public in 2026.

Both companies will begin trading on Friday under the ticker symbols COAG and SPTX, joining a recent series of large biotech IPOs that have raised almost $3.2 billion this year.